US Patent
US10675325 — Stable formulations of linaclotide
Formulation · Assigned to Forest Laboratories Holdings ULC · Expires 2031-08-11 · 5y remaining
Vulnerability score
48/100
Strong — defensible against typical IPR challenges
What this patent protects
This patent protects stable pharmaceutical compositions of linaclotide or its pharmaceutically acceptable salts.
USPTO Abstract
The present invention relates to stable pharmaceutical compositions comprising linaclotide or pharmaceutically acceptable salts thereof, as well as to various methods and processes for the preparation and use of the compositions.
Drugs covered by this patent
- Linzess (LINACLOTIDE) · AbbVie
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.